CA1261269A - Herpes simplex treatment - Google Patents
Herpes simplex treatmentInfo
- Publication number
- CA1261269A CA1261269A CA000473085A CA473085A CA1261269A CA 1261269 A CA1261269 A CA 1261269A CA 000473085 A CA000473085 A CA 000473085A CA 473085 A CA473085 A CA 473085A CA 1261269 A CA1261269 A CA 1261269A
- Authority
- CA
- Canada
- Prior art keywords
- composition
- vitamin
- bis
- diacetate
- phenol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 208000009889 Herpes Simplex Diseases 0.000 title claims abstract description 21
- 238000011282 treatment Methods 0.000 title claims description 10
- 239000000203 mixture Substances 0.000 claims abstract description 24
- KHOITXIGCFIULA-UHFFFAOYSA-N Alophen Chemical compound C1=CC(OC(=O)C)=CC=C1C(C=1N=CC=CC=1)C1=CC=C(OC(C)=O)C=C1 KHOITXIGCFIULA-UHFFFAOYSA-N 0.000 claims abstract description 14
- 208000015181 infectious disease Diseases 0.000 claims abstract description 5
- 239000004480 active ingredient Substances 0.000 claims abstract 6
- 239000003937 drug carrier Substances 0.000 claims abstract 2
- 239000002775 capsule Substances 0.000 claims description 13
- 229930003231 vitamin Natural products 0.000 claims description 13
- 239000011782 vitamin Substances 0.000 claims description 13
- 235000013343 vitamin Nutrition 0.000 claims description 13
- 229940088594 vitamin Drugs 0.000 claims description 13
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 8
- 239000002702 enteric coating Substances 0.000 claims description 6
- 238000009505 enteric coating Methods 0.000 claims description 6
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 5
- 239000008101 lactose Substances 0.000 claims description 5
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 4
- 229920002472 Starch Polymers 0.000 claims description 4
- 150000001413 amino acids Chemical class 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims description 4
- 235000018102 proteins Nutrition 0.000 claims description 4
- 108090000623 proteins and genes Proteins 0.000 claims description 4
- 102000004169 proteins and genes Human genes 0.000 claims description 4
- 235000019698 starch Nutrition 0.000 claims description 4
- 239000008107 starch Substances 0.000 claims description 4
- 229940124597 therapeutic agent Drugs 0.000 claims description 4
- 108010010803 Gelatin Proteins 0.000 claims description 3
- 108010061711 Gliadin Proteins 0.000 claims description 3
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 3
- 239000004472 Lysine Substances 0.000 claims description 3
- 150000001720 carbohydrates Chemical class 0.000 claims description 3
- 235000014633 carbohydrates Nutrition 0.000 claims description 3
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 2
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims description 2
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 claims description 2
- 208000036142 Viral infection Diseases 0.000 claims description 2
- 229930003268 Vitamin C Natural products 0.000 claims description 2
- 229930003427 Vitamin E Natural products 0.000 claims description 2
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 claims description 2
- 229960000304 folic acid Drugs 0.000 claims description 2
- 235000019152 folic acid Nutrition 0.000 claims description 2
- 239000011724 folic acid Substances 0.000 claims description 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 2
- 229920000159 gelatin Polymers 0.000 claims description 2
- 239000008273 gelatin Substances 0.000 claims description 2
- 235000019322 gelatine Nutrition 0.000 claims description 2
- 235000011852 gelatine desserts Nutrition 0.000 claims description 2
- 238000002347 injection Methods 0.000 claims description 2
- 239000007924 injection Substances 0.000 claims description 2
- 235000001968 nicotinic acid Nutrition 0.000 claims description 2
- 229960003512 nicotinic acid Drugs 0.000 claims description 2
- 239000011664 nicotinic acid Substances 0.000 claims description 2
- 230000009385 viral infection Effects 0.000 claims description 2
- 235000019155 vitamin A Nutrition 0.000 claims description 2
- 239000011719 vitamin A Substances 0.000 claims description 2
- 235000019154 vitamin C Nutrition 0.000 claims description 2
- 239000011718 vitamin C Substances 0.000 claims description 2
- 235000019165 vitamin E Nutrition 0.000 claims description 2
- 229940046009 vitamin E Drugs 0.000 claims description 2
- 239000011709 vitamin E Substances 0.000 claims description 2
- -1 mono-saccharide sugars Chemical class 0.000 claims 2
- 235000000346 sugar Nutrition 0.000 claims 2
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 claims 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 claims 1
- 229930003316 Vitamin D Natural products 0.000 claims 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 claims 1
- 235000001014 amino acid Nutrition 0.000 claims 1
- 239000006193 liquid solution Substances 0.000 claims 1
- 239000006194 liquid suspension Substances 0.000 claims 1
- 235000019166 vitamin D Nutrition 0.000 claims 1
- 239000011710 vitamin D Substances 0.000 claims 1
- 150000003710 vitamin D derivatives Chemical class 0.000 claims 1
- 229940045997 vitamin a Drugs 0.000 claims 1
- 229940046008 vitamin d Drugs 0.000 claims 1
- 238000000034 method Methods 0.000 abstract description 5
- 150000002148 esters Chemical class 0.000 description 20
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 18
- KJFMBFZCATUALV-UHFFFAOYSA-N phenolphthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2C(=O)O1 KJFMBFZCATUALV-UHFFFAOYSA-N 0.000 description 8
- 230000003902 lesion Effects 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 230000002475 laxative effect Effects 0.000 description 4
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- WNZQDUSMALZDQF-UHFFFAOYSA-N 2-benzofuran-1(3H)-one Chemical compound C1=CC=C2C(=O)OCC2=C1 WNZQDUSMALZDQF-UHFFFAOYSA-N 0.000 description 2
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 2
- 206010067152 Oral herpes Diseases 0.000 description 2
- 208000003251 Pruritus Diseases 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000007803 itching Effects 0.000 description 2
- 239000008141 laxative Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- CPJSUEIXXCENMM-UHFFFAOYSA-N phenacetin Chemical compound CCOC1=CC=C(NC(C)=O)C=C1 CPJSUEIXXCENMM-UHFFFAOYSA-N 0.000 description 2
- 239000008159 sesame oil Substances 0.000 description 2
- 235000011803 sesame oil Nutrition 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- CSDSSGBPEUDDEE-UHFFFAOYSA-N 2-formylpyridine Chemical compound O=CC1=CC=CC=N1 CSDSSGBPEUDDEE-UHFFFAOYSA-N 0.000 description 1
- RZAVMTCGIWKQJA-UHFFFAOYSA-N 3-(4-hydroxyphenyl)-3h-2-benzofuran-1-one Chemical compound C1=CC(O)=CC=C1C1C2=CC=CC=C2C(=O)O1 RZAVMTCGIWKQJA-UHFFFAOYSA-N 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 208000001688 Herpes Genitalis Diseases 0.000 description 1
- 208000004898 Herpes Labialis Diseases 0.000 description 1
- 241000701074 Human alphaherpesvirus 2 Species 0.000 description 1
- 206010037898 Rash vesicular Diseases 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 241000906446 Theraps Species 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 229940040526 anhydrous sodium acetate Drugs 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- 125000006267 biphenyl group Chemical group 0.000 description 1
- 229960000503 bisacodyl Drugs 0.000 description 1
- 239000004067 bulking agent Substances 0.000 description 1
- 239000007963 capsule composition Substances 0.000 description 1
- 230000035568 catharsis Effects 0.000 description 1
- SOYKEARSMXGVTM-UHFFFAOYSA-N chlorphenamine Chemical compound C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Cl)C=C1 SOYKEARSMXGVTM-UHFFFAOYSA-N 0.000 description 1
- 229960003291 chlorphenamine Drugs 0.000 description 1
- 229940070348 chlorpheniramine maleate 2 mg Drugs 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229940099112 cornstarch Drugs 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- DLNKOYKMWOXYQA-UHFFFAOYSA-N dl-pseudophenylpropanolamine Natural products CC(N)C(O)C1=CC=CC=C1 DLNKOYKMWOXYQA-UHFFFAOYSA-N 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 210000001752 female genitalia Anatomy 0.000 description 1
- 229940089653 folic acid 0.3 mg Drugs 0.000 description 1
- 201000004946 genital herpes Diseases 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 210000000260 male genitalia Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229940089654 niacin 13.5 mg Drugs 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000008855 peristalsis Effects 0.000 description 1
- 229960003893 phenacetin Drugs 0.000 description 1
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N phenylbenzene Natural products C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 1
- 229960001802 phenylephrine Drugs 0.000 description 1
- SONNWYBIRXJNDC-VIFPVBQESA-N phenylephrine Chemical compound CNC[C@H](O)C1=CC=CC(O)=C1 SONNWYBIRXJNDC-VIFPVBQESA-N 0.000 description 1
- DLNKOYKMWOXYQA-APPZFPTMSA-N phenylpropanolamine Chemical compound C[C@@H](N)[C@H](O)C1=CC=CC=C1 DLNKOYKMWOXYQA-APPZFPTMSA-N 0.000 description 1
- 229960000395 phenylpropanolamine Drugs 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
ABSTRACT OF THE DISCLOSURE
There is disclosed a method for treating Herpes Simplex infection condition which includes administering to a person having said condition an effective dosage of phenol, 4,4'-(2-pyridinyl methylene) bis,-diacetate (ester). Also disclosed are appropriate dosage compositions, normally containing 0.1-3.5 mg of active ingredient in association with a pharmaceutically acceptable carrier.
There is disclosed a method for treating Herpes Simplex infection condition which includes administering to a person having said condition an effective dosage of phenol, 4,4'-(2-pyridinyl methylene) bis,-diacetate (ester). Also disclosed are appropriate dosage compositions, normally containing 0.1-3.5 mg of active ingredient in association with a pharmaceutically acceptable carrier.
Description
M247:15990:WP~
HERPES SIMPLEX TREATMENT
Technical Field This invention relates to treatment of Herpes Simplex (Herpesvirus Hominis), a viral disease of widespread occurrence. Herpes Simplex occurs in two antigenic tyes, Herpes febrilis and Herpes genitalis, referred as Type 1 and Type 2. Infection is usually manifested by the appearance of vesicular eruptions, oral herpetic lesions, commonly referred to as fever blisters, or cold sores about the lips in the instance of Herpes Simplex Type l, and vesicular lesions on and about the male or female genitalia in the instance of Herpes Simplex Type 2. Persons with Herpes Simplex infections are likely to have recurrent periods of - lesion development spaced by periods of remission.
HERPES SIMPLEX TREATMENT
Technical Field This invention relates to treatment of Herpes Simplex (Herpesvirus Hominis), a viral disease of widespread occurrence. Herpes Simplex occurs in two antigenic tyes, Herpes febrilis and Herpes genitalis, referred as Type 1 and Type 2. Infection is usually manifested by the appearance of vesicular eruptions, oral herpetic lesions, commonly referred to as fever blisters, or cold sores about the lips in the instance of Herpes Simplex Type l, and vesicular lesions on and about the male or female genitalia in the instance of Herpes Simplex Type 2. Persons with Herpes Simplex infections are likely to have recurrent periods of - lesion development spaced by periods of remission.
2~ Management of the condition involves easing the itching sensation which accompanies the lesion periods, and speeding remission.
Background Art While no cure is presently known for Herpes Simplex in either form, certain substances have been advanced for management of the disease. In U.S~P. 4,256,763 to McHugh a method of treating inflammatory viral infections such as Herpes Simplex and acne was ; 35 ' ~
. . _s I
~ 3 1 dIsclosed involving the application of 3,3-bis (p-hydroxyphenyl) phthalide, in amounts up to lO0 milligrams, preferably 15 to 30 milligrams initially and repetitively at predetermined intervals.
Because 3,3-bis (p-hydroxyphenyl) phthalide is a cathartic, there is an unpleasant side effect ~o its use which suggests reduced usage concentratiorls, but the patentee does not suggest any lower dosage will be efEective in Herpes Simplex management.
Summary of the Invention -It is an object of the present invention to provide an effective Herpes Simplex treatment at much reduced dosage levels to minimize side effects. It is another object to provide a new ~se for phenol, 4,4'-(2-pyridinyl methylene) bis diacetate (ester).
It is a further object to provide for the rapid amelioration of Herpes Simplex symptoms, itching, lesion development and the like, by treatment with quite low quantities of phenol, 4,4'-(2-pyridinyl methylene) bis diacetate (ester), and to maintain the patient in a remissive state with continued low dosage treatment after remission. Still other objects include provision of products comprising phenol, 4,4'-(2-pyridinyl methylene) bis diacetate (ester), carriers and therapeutic agents for coapplication with phenol, ~,4'-(2-pyridinyl methylene) bis diacetate (ester).
- These and other objects of the invention to become ``
apparent hereinafter, are realized in accordance with the invention in the method of treatment of Herpes Simplex infection condition which includes administering an effective dosage of phenol, 4,4'-(2-pyridinyl methylene) bis,- diacetate (ester) to a person having an , . ~ ..
' ''~
-~
~ 3 1 Herpes Simplex condtion.
In particular embodiments, the method includes administering such dosage orally, administering a dosage of from about 0.1 to about 9.5 milligrams of phenol, 4,4'-(2-pyridinyl methylene) bis diacetate (ester), suspending the phenol, 4,4'-(2-pyridinyl methylene) bis,- diacetate (ester) in a carrier for administration, combining the phenol, 4,4'-(2-pyridinyl methylene) bis,- diacetate (ester) with a second therapeutic agent in an effective dosage for administration therewith, e.g. by selecting an effective dosage of one or more vitamins for coadministration with the phenol, 4,4'-t2-PYridinYl methylene) bis diacetate (ester), and carrier if any, and maintaining the phenol, 4,4'-(2-pyridinyl methylene) bis,- diacetate (ester) free of enteric coating for administration.
The invention further contemplates provision of a product comprising a dosage of phenol, 4,4'-~2-pyridinyl methylene) bis, diacetate (ester) effective upon oral ingestion- for management of Herpes Simplex, and less than is effective for catharsis of the person receiving the dosage and combined with an ingestible carrier. Typically, the product comprises a dosage between 0.1 and 9.5 milligrams, and may further comprise one or more vitamins in effective dosage, preferably free of an enteric coating.
..
''~
15990 -~-l Preferred Modes _ _ .
Phenol, 4,4'-(2-pyridinyl methylene) bis diacetate (ester~, commonly referred to as Bisacodyl, is a diphenyl trimethane suitably prepared from 2-pyridine-carboxaldehyde condensed with phenol in the presenceof sulfuric acid or other dehydrant, followed by esterification with acetic anhydride and anhydrous sodium acetate, as described in U.S.P. 2l764,590. It is a white to off-white crystalline powder slightly soluble in water but fairly soluble in common organic solvents. It is known to be used as a contact laxative, acting to increase peristalsis throughout the large intestlne. A typical dose as a laxative is oral or rectal not less than 10 milligrams and up to 30 milligrams and is administered in an enteric coating to ensure passage to the larage intestine. It is known to inhibit glucose absorption and intestinal Na-K-ATPase activity.
The effectiveness of phenol, 4,4'-(2-pyridinyl methylene) bis,- diacetate (ester) in treatment of Herpes Simplex is not to be expected from a study of its past usages or chemical structure, and is not scientifically explainable at this time. It has been found surprisingly effective in Herpes Simplex management, causing nearly immediate remission and suppressing recurrence, although administered at quite moderate levels, less than those recommended for laxative action, and far less than 3,3-bis (p-hydroyphenyl) phthalide dosages recommended in U.S.P.
4,256,7~3. The use of phenol, 4,4'-(2-pyridinyl methylene) bis,- diacetate (ester) as taught herein thus enables Herpes Simplex management with reduced .
~'' '''~
~. ~
' ` ~
.
; '. ~, ' 15990 _5_ 1 incidence of side effects than encountered with the use of alternate methodologies.
The phenol, 4,4'-(2-pyridinyl methylene) bis,-diacetate (s~ter) may be combined with other therap~utic agents each for its own purpose e.g. to reli~ve stress, or to enhance the ef~ectivenes~ of the phenol, 4,4'-(2-pyridinyl methylene) bis,- diacetate (ester~ when administered. Such agents as vitamins A, D, E, C, Folic acid, 3-1, B-2, Niacin, B-6, and B-12, among others can be comblned with the phenol, 4,4'-~2-pyridinyl methylene) bis diacetate (ester). Other agents for combining with phenol, 4,4'-(2-pyridinyl methylcnc) bi~
diacetate (ester) include amino acids, such as lysine and leucine; proteins such as gelatin and gliadin; or carbohydrates, e.g. starch, lactose and the likc.
Whether administered orally, topically or intra-venously, ~he phenol, 4,4'-(2-pyridinyl me~hylene) bis,- diacetate ~ester) may be suitably dispersed in a carrier, e.g. tablet or capsule carriers and components such as cxcipients, bulking agents, lubricants, disintegrants, dyes and the like as are known in tablet ma~ing technology for the purposc of easing the administration of the phenol, 4,4'-(2-pyridinyl methylene) bis diacetate ~ester). The term carrier further embraces vehicles used or useful in preparing injection form o the phenol, 4,4'-(2-pyridinyl methylene) bis,-diacetate (ester) prioducts of the invention, such as sesame oil and the like.
It is convenient to provide capsules or tablets of the composition according to the invention in sets or groups, of a sufficient number and strength to constitute a daily dosage of an appropriate amount. A typical total daily dose is ~rom about 10 to about 13 mg, and it is conveniently provided in 3-4 mg units ~capsules or tablets), ~5 one uni~ to be taken orally at intervals of 6-12 hours to -5a-provide the appropriate total daily dose.
EXAMPLE I
Capsules of phe'n,ol, 4,4'-(2-pyridinyl methylene) bis,-diacetate (ester) were prepared by mixing per :
:
: ~ : : : :
:
.
t;'3 l5990 ; -6-1 capsule 3.35 milligrams of phenol, 4,4'-(2-pyridinyl methylene) bis,- diacetate ~ester) with 490 milligrams of an aliquot of a mixture oE vitamins comprising:
Vitamin A2500 units Vitamin D400 units Vitamin E15 units Vitamin C 60 mg.
Folic acid 0.3 mg.
Vitamin B-l 1.0 mg.
Vitamin B-2 1.2 mg.
Niacin 13.5 mg.
Vitamin B-6 1.0 mg.
Vitamin B-12 4.5 mg.
blended with 2 parts of cornstarch per part of vitamin mix.
Adult males having a virulent recurrence of Herpes Simplex Types 1 and 2 were given a series of EXAMPLE
I capsules prepared as above, or a like CONTROL I
capsule prepared with phenolphthalein 3,3-bis (p-hydroxyphenyl phthalide) rather than phenol, 4,4'-(2-pyridinyl methylene) bis diacetate [ester), or a CONTROL II as taught in U.S~P. 4,256,763. The CONTROL II capsules comprised:
Phenolphthalein 30 mg.
Acetominophen325 mg.
Chlorpheniramine Maleate2 mg. ``
; Caffein 33 mg.
Phenylephrine HCL 10 mg.
The effective dosage rate for the CONTROL I and II
treatments was 30 milligrams per 8 hours for the first day, and a like amount at 12 hour intervals .
., .
15990 ~7~
thereafter. The EXAMPLE I dosage rate was one capsule (3.35 mg. per dosage) every six to eight hours on the first day and thereafter at 8 to 12 hour intervals.
All subjects showed rapid remission. The EXAMPLE
I material was no less effective for being at the reduced dosage rate, and incidence of diarrhea from the laxative effect was less of a problem than with the CONTROL I and II tests.
The inclusion of vitamins in the EXA.~PLE I
formulation adds stress relief factors to the formulation to ameliorate the stress which often accompanies onset of a Herpes condition.
EXA.~PLE II
A second capsule formula of the invention composition ~as prepared from:
phenol, 4~4'-(2-pyridinyl methylene) bis diacetate ~ester)3.5 mg.
phenacetin 350. mg.
chloropheniramine maleate3. mg.
caffein 38. mg.
phenylpropanolamine HCL9. mg.
by blending the ingredients eutectically.
EXAMPLE III
A tablet form of the invention dosage is prepared by blending phenol, 4,4'-(2-pyridinyl methylene) bis diacetate (ester), 3.5 mg., 100 mg. lactose, 100 mgO
starch, and 10 mg. taic as a lubricant. It will be noted that this formulation can be packaged in bapsule form with the omission of the talc and adjusting ~he lactose and starch concentration`accordingly.
.
. ' ' ;~. . .
...........
i9 EXAMPLE IV
A protein containing capsule is prepared by blending eutectlcally phenol, 4,4'--(2-pyridinyl methylene) bis diacetate (ester), 3.5 mg., 200 mg. lactose, 100 mg.
gliadin or gelatin protein, and about 100 mg. of the amino acid lysine.
EXAMPLE V
An intramuscular injectable formulation is prepared by blending, per dosage, 5 cc. sesame oil, 250 units of Vitamin E, and 5 mg. of phenol, 4,4'-(2-pyridinyl methylene) bls diacetate (ester).
'`''` '' ... . . ...
Background Art While no cure is presently known for Herpes Simplex in either form, certain substances have been advanced for management of the disease. In U.S~P. 4,256,763 to McHugh a method of treating inflammatory viral infections such as Herpes Simplex and acne was ; 35 ' ~
. . _s I
~ 3 1 dIsclosed involving the application of 3,3-bis (p-hydroxyphenyl) phthalide, in amounts up to lO0 milligrams, preferably 15 to 30 milligrams initially and repetitively at predetermined intervals.
Because 3,3-bis (p-hydroxyphenyl) phthalide is a cathartic, there is an unpleasant side effect ~o its use which suggests reduced usage concentratiorls, but the patentee does not suggest any lower dosage will be efEective in Herpes Simplex management.
Summary of the Invention -It is an object of the present invention to provide an effective Herpes Simplex treatment at much reduced dosage levels to minimize side effects. It is another object to provide a new ~se for phenol, 4,4'-(2-pyridinyl methylene) bis diacetate (ester).
It is a further object to provide for the rapid amelioration of Herpes Simplex symptoms, itching, lesion development and the like, by treatment with quite low quantities of phenol, 4,4'-(2-pyridinyl methylene) bis diacetate (ester), and to maintain the patient in a remissive state with continued low dosage treatment after remission. Still other objects include provision of products comprising phenol, 4,4'-(2-pyridinyl methylene) bis diacetate (ester), carriers and therapeutic agents for coapplication with phenol, ~,4'-(2-pyridinyl methylene) bis diacetate (ester).
- These and other objects of the invention to become ``
apparent hereinafter, are realized in accordance with the invention in the method of treatment of Herpes Simplex infection condition which includes administering an effective dosage of phenol, 4,4'-(2-pyridinyl methylene) bis,- diacetate (ester) to a person having an , . ~ ..
' ''~
-~
~ 3 1 Herpes Simplex condtion.
In particular embodiments, the method includes administering such dosage orally, administering a dosage of from about 0.1 to about 9.5 milligrams of phenol, 4,4'-(2-pyridinyl methylene) bis diacetate (ester), suspending the phenol, 4,4'-(2-pyridinyl methylene) bis,- diacetate (ester) in a carrier for administration, combining the phenol, 4,4'-(2-pyridinyl methylene) bis,- diacetate (ester) with a second therapeutic agent in an effective dosage for administration therewith, e.g. by selecting an effective dosage of one or more vitamins for coadministration with the phenol, 4,4'-t2-PYridinYl methylene) bis diacetate (ester), and carrier if any, and maintaining the phenol, 4,4'-(2-pyridinyl methylene) bis,- diacetate (ester) free of enteric coating for administration.
The invention further contemplates provision of a product comprising a dosage of phenol, 4,4'-~2-pyridinyl methylene) bis, diacetate (ester) effective upon oral ingestion- for management of Herpes Simplex, and less than is effective for catharsis of the person receiving the dosage and combined with an ingestible carrier. Typically, the product comprises a dosage between 0.1 and 9.5 milligrams, and may further comprise one or more vitamins in effective dosage, preferably free of an enteric coating.
..
''~
15990 -~-l Preferred Modes _ _ .
Phenol, 4,4'-(2-pyridinyl methylene) bis diacetate (ester~, commonly referred to as Bisacodyl, is a diphenyl trimethane suitably prepared from 2-pyridine-carboxaldehyde condensed with phenol in the presenceof sulfuric acid or other dehydrant, followed by esterification with acetic anhydride and anhydrous sodium acetate, as described in U.S.P. 2l764,590. It is a white to off-white crystalline powder slightly soluble in water but fairly soluble in common organic solvents. It is known to be used as a contact laxative, acting to increase peristalsis throughout the large intestlne. A typical dose as a laxative is oral or rectal not less than 10 milligrams and up to 30 milligrams and is administered in an enteric coating to ensure passage to the larage intestine. It is known to inhibit glucose absorption and intestinal Na-K-ATPase activity.
The effectiveness of phenol, 4,4'-(2-pyridinyl methylene) bis,- diacetate (ester) in treatment of Herpes Simplex is not to be expected from a study of its past usages or chemical structure, and is not scientifically explainable at this time. It has been found surprisingly effective in Herpes Simplex management, causing nearly immediate remission and suppressing recurrence, although administered at quite moderate levels, less than those recommended for laxative action, and far less than 3,3-bis (p-hydroyphenyl) phthalide dosages recommended in U.S.P.
4,256,7~3. The use of phenol, 4,4'-(2-pyridinyl methylene) bis,- diacetate (ester) as taught herein thus enables Herpes Simplex management with reduced .
~'' '''~
~. ~
' ` ~
.
; '. ~, ' 15990 _5_ 1 incidence of side effects than encountered with the use of alternate methodologies.
The phenol, 4,4'-(2-pyridinyl methylene) bis,-diacetate (s~ter) may be combined with other therap~utic agents each for its own purpose e.g. to reli~ve stress, or to enhance the ef~ectivenes~ of the phenol, 4,4'-(2-pyridinyl methylene) bis,- diacetate (ester~ when administered. Such agents as vitamins A, D, E, C, Folic acid, 3-1, B-2, Niacin, B-6, and B-12, among others can be comblned with the phenol, 4,4'-~2-pyridinyl methylene) bis diacetate (ester). Other agents for combining with phenol, 4,4'-(2-pyridinyl methylcnc) bi~
diacetate (ester) include amino acids, such as lysine and leucine; proteins such as gelatin and gliadin; or carbohydrates, e.g. starch, lactose and the likc.
Whether administered orally, topically or intra-venously, ~he phenol, 4,4'-(2-pyridinyl me~hylene) bis,- diacetate ~ester) may be suitably dispersed in a carrier, e.g. tablet or capsule carriers and components such as cxcipients, bulking agents, lubricants, disintegrants, dyes and the like as are known in tablet ma~ing technology for the purposc of easing the administration of the phenol, 4,4'-(2-pyridinyl methylene) bis diacetate ~ester). The term carrier further embraces vehicles used or useful in preparing injection form o the phenol, 4,4'-(2-pyridinyl methylene) bis,-diacetate (ester) prioducts of the invention, such as sesame oil and the like.
It is convenient to provide capsules or tablets of the composition according to the invention in sets or groups, of a sufficient number and strength to constitute a daily dosage of an appropriate amount. A typical total daily dose is ~rom about 10 to about 13 mg, and it is conveniently provided in 3-4 mg units ~capsules or tablets), ~5 one uni~ to be taken orally at intervals of 6-12 hours to -5a-provide the appropriate total daily dose.
EXAMPLE I
Capsules of phe'n,ol, 4,4'-(2-pyridinyl methylene) bis,-diacetate (ester) were prepared by mixing per :
:
: ~ : : : :
:
.
t;'3 l5990 ; -6-1 capsule 3.35 milligrams of phenol, 4,4'-(2-pyridinyl methylene) bis,- diacetate ~ester) with 490 milligrams of an aliquot of a mixture oE vitamins comprising:
Vitamin A2500 units Vitamin D400 units Vitamin E15 units Vitamin C 60 mg.
Folic acid 0.3 mg.
Vitamin B-l 1.0 mg.
Vitamin B-2 1.2 mg.
Niacin 13.5 mg.
Vitamin B-6 1.0 mg.
Vitamin B-12 4.5 mg.
blended with 2 parts of cornstarch per part of vitamin mix.
Adult males having a virulent recurrence of Herpes Simplex Types 1 and 2 were given a series of EXAMPLE
I capsules prepared as above, or a like CONTROL I
capsule prepared with phenolphthalein 3,3-bis (p-hydroxyphenyl phthalide) rather than phenol, 4,4'-(2-pyridinyl methylene) bis diacetate [ester), or a CONTROL II as taught in U.S~P. 4,256,763. The CONTROL II capsules comprised:
Phenolphthalein 30 mg.
Acetominophen325 mg.
Chlorpheniramine Maleate2 mg. ``
; Caffein 33 mg.
Phenylephrine HCL 10 mg.
The effective dosage rate for the CONTROL I and II
treatments was 30 milligrams per 8 hours for the first day, and a like amount at 12 hour intervals .
., .
15990 ~7~
thereafter. The EXAMPLE I dosage rate was one capsule (3.35 mg. per dosage) every six to eight hours on the first day and thereafter at 8 to 12 hour intervals.
All subjects showed rapid remission. The EXAMPLE
I material was no less effective for being at the reduced dosage rate, and incidence of diarrhea from the laxative effect was less of a problem than with the CONTROL I and II tests.
The inclusion of vitamins in the EXA.~PLE I
formulation adds stress relief factors to the formulation to ameliorate the stress which often accompanies onset of a Herpes condition.
EXA.~PLE II
A second capsule formula of the invention composition ~as prepared from:
phenol, 4~4'-(2-pyridinyl methylene) bis diacetate ~ester)3.5 mg.
phenacetin 350. mg.
chloropheniramine maleate3. mg.
caffein 38. mg.
phenylpropanolamine HCL9. mg.
by blending the ingredients eutectically.
EXAMPLE III
A tablet form of the invention dosage is prepared by blending phenol, 4,4'-(2-pyridinyl methylene) bis diacetate (ester), 3.5 mg., 100 mg. lactose, 100 mgO
starch, and 10 mg. taic as a lubricant. It will be noted that this formulation can be packaged in bapsule form with the omission of the talc and adjusting ~he lactose and starch concentration`accordingly.
.
. ' ' ;~. . .
...........
i9 EXAMPLE IV
A protein containing capsule is prepared by blending eutectlcally phenol, 4,4'--(2-pyridinyl methylene) bis diacetate (ester), 3.5 mg., 200 mg. lactose, 100 mg.
gliadin or gelatin protein, and about 100 mg. of the amino acid lysine.
EXAMPLE V
An intramuscular injectable formulation is prepared by blending, per dosage, 5 cc. sesame oil, 250 units of Vitamin E, and 5 mg. of phenol, 4,4'-(2-pyridinyl methylene) bls diacetate (ester).
'`''` '' ... . . ...
3 0 - ~. - : :. ~ : . .. .. ~ . .- . - .
.. ... .
' ? { ~ ~ . . .` ` C ~
.
: . .
.,: . . ~ :: .
..
:. . :: :
.. ... .
' ? { ~ ~ . . .` ` C ~
.
: . .
.,: . . ~ :: .
..
:. . :: :
Claims (14)
1. A composition for administratlon to mammals to treat Herpes Simplex infections therein, said composition comprising an effective dosage amount as active ingredient of phenol, 4,4'-(2-pyridinyl methylene) bis, diacetate (ester) in association with a pharmaceutically acceptable carrier.
2. The composition of claim 1, wherein said dosage amount of active ingredient therein is from about 0.1 mg to about 9.5 mg.
3. The composition of claim 1, and free of enteric coating.
4. The composition of claim 2, in capsule or tablet form adapted for oral administration to a patient.
5. The composition of claim 1, claim 2 or claim 3, wherein said dosage amount of active ingredient therein is from about 0.1 mg to about 3.5 mg.
6. The composition of claim 1, claim 2 or claim 3, also including at least one other therapeutic agent selected from vitamins, amino acids, proteins and carbohydrates.
7. The composition of claim 1, claim 2 and claim 3, also including at least one other therapeutic agent selected from vitamin A, vitamin D, vitamin E, vitamin C, folic acid, vitamin B-l, vitamin B-2, niacin, vitamin B-6 and vitamin B-12, and mixtures of two or more said agents.
8. The composition of claim 1, claim 2 or claim 3, also including an amino acid selected from lysine and leucine.
9. The composition of claim 1, claim 2 or claim 3, also including a protein selected from gelatin and gliadin.
10. The composition of claim 1, claim 2 or claim 3, also including a carbohydrate selected from starch, lactose, mono-saccharide sugars and disaccharide sugars.
11. An effective daily dosage of a composition according to claim 3, for administration to a human patient for treatment of Herpes Simplex viral infections therein, and comprising a plurality of individual orally administrable capsules or tablets, each containing from about 3 mg to about 4 mg of phenol, 4,4'-(2-pyridinyl methylene) bis,-diacetate (ester) as active ingredient, the total number of said capsules or tablets being sufficient to provide a total dosage of from about 10 mg to about 13 mg of active ingredient for administration to the patient over a period of 24 hours.
12. The composition of claim 1 or claim 2, in liquid suspension or solution for administration to a patient by injection.
13. The composition of claim 2, and free of enteric coating.
14. The composition of claim 4, and free of enteric coating.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA000473085A CA1261269A (en) | 1985-01-29 | 1985-01-29 | Herpes simplex treatment |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA000473085A CA1261269A (en) | 1985-01-29 | 1985-01-29 | Herpes simplex treatment |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA1261269A true CA1261269A (en) | 1989-09-26 |
Family
ID=4129706
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA000473085A Expired CA1261269A (en) | 1985-01-29 | 1985-01-29 | Herpes simplex treatment |
Country Status (1)
| Country | Link |
|---|---|
| CA (1) | CA1261269A (en) |
-
1985
- 1985-01-29 CA CA000473085A patent/CA1261269A/en not_active Expired
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4588744A (en) | Method of forming an aqueous solution of 3-3-Bis(p-hydroxyphenyl)-phthalide | |
| Welling | Influence of food and diet on gastrointestinal drug absorption: a review | |
| US4256763A (en) | Treatment of herpes simplex infections and acne | |
| US6770635B1 (en) | Method for medicating the inflammatory controlling system and adverse inflammatory reactions and for making compounds for treating the pathology of adverse inflammatory reactions | |
| Morrison et al. | Vitamin absorption studies: I. Factors influencing the excretion of oral test doses of thiamine and riboflavin by human subjects | |
| US4314989A (en) | Methionine sulfoxide amflioration of acetaminophen toxicity | |
| US6558656B2 (en) | Oral and topical compositions and methods related thereto in the treatment of acne | |
| KR910005858A (en) | Fatty acid therapy | |
| US4034114A (en) | Treatment of skin keratoses with retinal | |
| US4576951A (en) | Proglumide, pharmaceutical preparations and compositions including it for use in human pain relief | |
| US3560612A (en) | Method of alleviating hypercitricemia | |
| US5151425A (en) | Method of and composition for treating inflammation and the immunological response thereto | |
| US4810707A (en) | Herpes simplex treatment | |
| CA1261269A (en) | Herpes simplex treatment | |
| US3019165A (en) | Sunburn preventive and burn remedy | |
| US4343799A (en) | Use of derivatives of 6α-methylprednisolone for the prevention or reduction of adriamycin-induced cardiotoxicity | |
| US4520132A (en) | Use of undecylenic acid to treat herpes labialis | |
| US4438129A (en) | Use of clotrimazole to treat herpes labialis | |
| NO974486L (en) | Low-dose "Ridogrel" formulations and their use in the treatment of intestinal inflammation | |
| WO1986000016A1 (en) | Herpes simplex treatment | |
| EG17992A (en) | Preparation of a medicament for arthritis and theumatism | |
| US4302452A (en) | Use of derivatives of 6α-methylprednisolone as an antiemetic | |
| CA1207238A (en) | Use of haloprogin in the treatment of herpes labialis | |
| Depre et al. | Plasma drug profiles and tolerability of MK-571 (L-660,711), a leukotriene D4 receptor antagonist, in man | |
| USRE32990E (en) | Use of undercylenic acid to treat herpes labialis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MKEX | Expiry |